News
IFRX
1.600
+4.58%
0.070
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at IFRX last week (0928-1002)?
Weekly Report · 6d ago
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Barchart · 10/02 06:30
Weekly Report: what happened at IFRX last week (0921-0925)?
Weekly Report · 09/28 09:10
Weekly Report: what happened at IFRX last week (0914-0918)?
Weekly Report · 09/21 09:10
This GE Vernova Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Benzinga · 09/14 12:23
InflaRx initiated with a Buy at Needham
TipRanks · 09/14 10:40
Weekly Report: what happened at IFRX last week (0907-0911)?
Weekly Report · 09/14 09:10
Weekly Report: what happened at IFRX last week (0831-0904)?
Weekly Report · 09/07 09:10
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/03 12:05
Weekly Report: what happened at IFRX last week (0824-0828)?
Weekly Report · 08/31 09:11
Weekly Report: what happened at IFRX last week (0817-0821)?
Weekly Report · 08/24 09:11
Weekly Report: what happened at IFRX last week (0810-0814)?
Weekly Report · 08/17 09:11
Here's Why We're Not At All Concerned With InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Simply Wall St · 08/11 11:06
Weekly Report: what happened at IFRX last week (0803-0807)?
Weekly Report · 08/10 09:10
InflaRx Price Target Raised to $6.00/Share From $4.00 by Cantor Fitzgerald
Dow Jones · 08/07 12:40
InflaRx Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 08/07 12:40
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Benzinga · 08/07 12:30
Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)
TipRanks · 08/07 00:50
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
TipRanks · 08/06 21:20
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.